Boehringer Ingelheim acquires T3 Pharma for $509m – Pharmaceutical Technology
Share this article T3 Pharma has repurposed the bacterial type III secretion system of Yersinia enterocolitica to deliver proteins to tumour cells. Image credit: Shutterstock/Kateryna